Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMaking sense of the tirzepatide naming puzzle, and what it means for your decision
The decision most UK readers are actually facing
You've probably landed here after seeing Zepbound mentioned on American news sites, Reddit threads, or social media posts from US users. The brand generates real excitement: tirzepatide produced greater average weight reduction than semaglutide 2.4mg in the SURMOUNT-5 head-to-head trial, published in the New England Journal of Medicine in 2025, and the results have travelled fast across the internet regardless of geography. So the real decision for someone in the UK is not Zepbound vs tirzepatide, it is which UK-licensed medicine is right for your situation.
The two options a UK prescriber can work with for weight management are Mounjaro (tirzepatide, Eli Lilly) and Wegovy (semaglutide, Novo Nordisk). Both are prescription-only medicines. Both require clinical assessment. The question of which suits you is one a prescriber answers after looking at your health history, not one a comparison article can settle. What this page can do is lay out the facts clearly so you arrive at that conversation better prepared.
One practical note: if you have been researching on and off for a few weeks, you may have noticed prices and availability shifting. That is real, Mounjaro's UK list price changed significantly from September 2025. Timing your start around a payday or a holiday week is understandable, but the clinical picture matters more than the calendar.
Zepbound vs Mounjaro: what the table actually shows
Because Zepbound and Mounjaro are chemically identical (same active ingredient, same strengths, same mechanism) a head-to-head comparison between them produces identical efficacy and safety data. The differences are regulatory and commercial, not clinical.
| Factor | Zepbound (US) | Mounjaro (UK) |
|---|---|---|
| Active ingredient | Tirzepatide | Tirzepatide |
| Manufacturer | Eli Lilly | Eli Lilly |
| Regulatory approval | FDA (United States) | MHRA (United Kingdom) |
| Licensed for weight management | Yes, in the US | Yes, in the UK (NICE TA1026) |
| Available from UK pharmacies | No | Yes, via prescription |
| Weight-loss trial evidence (15mg, 72 weeks) | SURMOUNT-1: ~20–21% average body-weight reduction [SURMOUNT-1, NEJM] | Same data, same molecule |
The table underlines the point: the clinical evidence base is shared because the drug is shared. Seeking Zepbound from an overseas or unverified source to access tirzepatide is not a workaround, it is a route that bypasses UK clinical safeguards and the MHRA-regulated supply chain. The licensed route to tirzepatide in the UK is through a GPhC-registered pharmacy following a valid prescription.
How tirzepatide compares with semaglutide, the clinically meaningful question
If you want a genuine comparison relevant to a UK prescription decision, the more useful one is tirzepatide (Mounjaro) against semaglutide (Wegovy). Tirzepatide works on two gut-hormone receptors (GIP and GLP-1) while semaglutide targets GLP-1 alone. In practice, both slow gastric emptying, reduce appetite and support sustained weight loss, but the mechanisms differ and so can individual responses. You can read a fuller breakdown on our tirzepatide vs Mounjaro page, which also covers how the two interact with the NHS access framework.
The SURMOUNT-5 trial found greater average weight loss with tirzepatide than with semaglutide 2.4mg at 72 weeks in adults with obesity and no diabetes. Wegovy's 7.2mg dose, approved by the MHRA in 2026, narrows that gap somewhat, trial data for the higher dose showed around 20.7% average reduction over 72 weeks. Neither figure is a guarantee for any individual patient; biology, dose tolerance, and lifestyle factors all shape real-world outcomes. You can find the NHS's patient-level overview of both medicines at the NHS tirzepatide page.
For those curious about how other emerging treatments sit alongside tirzepatide, our GLP-1 vs tirzepatide page covers the broader drug class in plain terms.
What a UK prescriber considers, and how to get there
Because both Mounjaro and Wegovy are prescription-only medicines, the decision is ultimately clinical. A prescriber looks at your BMI, any weight-related health conditions, medication history, and contraindications before recommending a treatment. Neither medicine is simply dispensed on request. The licensed eligibility window for Mounjaro in the UK covers adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition such as high blood pressure, type 2 diabetes or high cholesterol, though BMI alone is never the whole picture. NICE's appraisal of tirzepatide sets out a separate threshold for NHS prescribing, detailed at NICE TA1026.
At nume, a GPhC-registered Independent Prescriber reads every consultation personally, on the same day. There is no algorithm making clinical calls. If you want to understand what that process looks like, our about page covers how the service is structured, and our clinical team profile is on the prescribers page. For those weighing up newer agents further along in development, the retatrutide vs tirzepatide page gives an early evidence overview.
Which licensed UK treatment suits you is a clinical decision, one our prescribers work through with you. To start that conversation, check your eligibility with a free consultation.
Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.